Improving viral vector safety for gene therapies
Drug Discovery World
AUGUST 21, 2024
The composition of engineered cells in vivo can change over time as clones proliferate at varying rates. Following initial viral vector transduction, treated samples, typically whole blood and/or enriched cell populations, are collected and the genomic DNA is isolated. The frequency of AAV integration has been estimated at 0.1%
59 
Let's personalize your content